TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02816086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interdisciplinary collaboration structure
Description: A pharmacist is integrated in the team surrounding the patient, working by the Integrated Medicines Management (IMM) model. The IMM-model consist of medication reconciliation, medication review, standardized medication reports and counseling patients about their medication at discharge. In addition a phone meeting between the primary care physician and the study pharmacist is added after discharge.
Study: NCT01218529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Co-administration of lapatinib 1250mg once daily during the WBRT period (2 weeks)and then monotherapy with lapatinib 1500mg once daily for 4 weeks.
Study: NCT03891953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKY709
Description: Novel immunomodulatory agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKY709
Description: Novel immunomodulatory agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: PDR001 is a high-affinity, ligand-blocking, humanized IgG4 monoclonal antibody directed against PD-1 that blocks the binding of PD-L1 and PD-L2
Study: NCT04154774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Apalutamide will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Apalutamide will be administered orally.
Study: NCT03937219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Specified dose on specified days.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Specified dose on specified days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Specified dose on specified days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabozantinib-matched placebo
Description: Specified dose on specified days.
Study: NCT02106988

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy delivered for a total dose of 50.4 to 54 Gy 5 days a week for 28 to 30 treatments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg by vein Days 1-3 in a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide phosphate
Description: 67 mg/m2 by vein on Days 1-3 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 1 g/m2 by vein on Days 1-3 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 0.4 g/m2 by vein on Days 1-3 with Ifosfamide, 0.6 g/m2 by vein over 24 hours daily on Days 1-3 via ambulatory pump.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: 200 mg/m2 by vein on Day 1 of a 21 day cycle.
Study: NCT04502550

Intervention type: DRUG
Intervention: Propofol
Description: Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.

Intervention type: DRUG
Intervention: Propofol
Description: Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.

Intervention type: DRUG
Intervention: Propofol
Description: Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.

Intervention type: DRUG
Intervention: Propofol
Description: Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.

Intervention type: DRUG
Intervention: Propofol
Description: Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.

Intervention type: DRUG
Intervention: Propofol
Description: Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.

Intervention type: DRUG
Intervention: Propofol
Description: Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.
Study: NCT03635489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m\^2 IV infusion on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: 175 mg/m\^2 IV infusion on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg IV infusion on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Area Under the Curve (AUC) of 6 mg/ml/min on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Area Under the Curve (AUC) of 6 mg/ml/min on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to bevacizumab IV infusion on Day 1 of each 21-day cycle.
Study: NCT03624517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: Octreotide infusion for 24-hours in patients with bleeding esophageal varices.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: Octreotide infusion for 24-hours in patients with bleeding esophageal varices.
Study: NCT03501329

Intervention type: COMBINATION_PRODUCT
Intervention: Biological,Psychological and Social support
Study: NCT01741116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI258
Description: Investigational treatment refers to TKI258 in this study Until Progression, unacceptable toxicity, withdrawal
Study: NCT00925821

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic stem cell transplant versus second autologous transplantation
Description: Transplantation of stem cells from a MRD or MUD, respectively after dose-reduced conditioning versus autologous stem cell graft after preparation with melphalan 200 mg/m²

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: allogeneic stem cell transplant versus second autologous transplantation
Description: Transplantation of stem cells from a MRD or MUD, respectively after dose-reduced conditioning versus autologous stem cell graft after preparation with melphalan 200 mg/m²

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD
Description: After enrollment, patients are to receive four cycles of RAD induction treatment: a combination of lenalidomide (Revlimid), adriamycin, and dexamethasone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RAD
Description: After enrollment, patients are to receive four cycles of RAD induction treatment: a combination of lenalidomide (Revlimid), adriamycin, and dexamethasone.
Study: NCT01547299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride
Study: NCT03145571

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Continuity of midwifery care
Description: Pre-natal care in rural villages performed by the midwives from the local hospital
Study: NCT03682705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elsubrutinib
Description: Elsubrutinib capsule will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elsubrutinib
Description: Elsubrutinib capsule will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elsubrutinib
Description: Elsubrutinib capsule will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elsubrutinib
Description: Elsubrutinib capsule will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Upadacitinib tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Upadacitinib tablet will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for elsubrutinib
Description: Placebo capsule for elsubrutinib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for elsubrutinib
Description: Placebo capsule for elsubrutinib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for upadacitinib
Description: Placebo tablet for upadacitinib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for upadacitinib
Description: Placebo tablet for upadacitinib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for upadacitinib
Description: Placebo tablet for upadacitinib will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for upadacitinib
Description: Placebo tablet for upadacitinib will be administered orally.
Study: NCT03392207

Intervention type: BIOLOGICAL
Intervention: Seasonal Influenza Vaccine
Description: Trivalent, Fragmented, Inactivated Seasonal Influenza Vaccine (2018 Southern Hemisphere Season) produced at Butantan Institute
Study: NCT03489018

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV10
Description: Experimental arms will receive a lower dose of the intervention than the marketed dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV10
Description: Experimental arms will receive a lower dose of the intervention than the marketed dose.
Study: NCT02162303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: 0.6 mg a day of active treatment or placebo for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar,given once daily, over 6 months.To mimic active treatment
Study: NCT02094521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0113-0987
Description: For oral administration. All subjects will be treated for 10 consecutive days with five days on 5 mg NNC0113-0987 followed by five days on 10 mg NNC0113-0987. Dose escalation is chosen to increase gastrointestinal tolerability.
Study: NCT02629211

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NaviAid™ AB
Description: NaviAid™ AB Procedure
Study: NCT04244851

Intervention type: OTHER
Intervention: Malnourished patients
Description: Data of included patients will be recorded during hospitalization using medical charts.~Every patient will be contacted by phone 3 months after hospital discharge. A sample of patients and their caregivers will be interviewed to better understand their perception of malnutrition and what they need to better take care of malnutrition.
Study: NCT00628836

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BION stimulation
Description: The study will have two phases, each with a six week duration. During phase 1, the BION group will be implanted with BIONs in the middle deltoid and supraspinatus muscles. The muscles will be stimulated electrically by way of the BION and an external controller for one to two hours per day at 5pps in an on-off duty cycle train. The SE group will begin surface stimulation similar to that of BE group.~Subjects in either group whose initial therapy in phase 1 successfully reduces the amount of shoulder subluxation to 5mm or less will go off stimulation for six weeks, and be reassessed whether subluxation is redeveloping.~If a subject in either group does not respond sufficiently to phase 1 therapy, the participant will move to phase 2 where the shoulder will be stimulated at up to 25 pps either with surface stimulation (SE group) or BION stimulation (BE group) for another six weeks. At the end of phase 2, participants will go off stimulation for six weeks and then be reevaluated.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BION stimulation
Description: The study will have two phases, each with a six week duration. During phase 1, the BION group will be implanted with BIONs in the middle deltoid and supraspinatus muscles. The muscles will be stimulated electrically by way of the BION and an external controller for one to two hours per day at 5pps in an on-off duty cycle train. The SE group will begin surface stimulation similar to that of BE group.~Subjects in either group whose initial therapy in phase 1 successfully reduces the amount of shoulder subluxation to 5mm or less will go off stimulation for six weeks, and be reassessed whether subluxation is redeveloping.~If a subject in either group does not respond sufficiently to phase 1 therapy, the participant will move to phase 2 where the shoulder will be stimulated at up to 25 pps either with surface stimulation (SE group) or BION stimulation (BE group) for another six weeks. At the end of phase 2, participants will go off stimulation for six weeks and then be reevaluated.
Study: NCT02459158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME1100 inhalation solution
Description: Low dose of ME1100 inhalation solution twice daily for up to 14 days to be administered via eFlow nebulizer system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME1100 inhalation solution
Description: High dose of ME1100 inhalation solution twice daily for up to 14 days to be administered via eFlow nebulizer system
Study: NCT03565068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: MK-8189 4 mg tablet(s) will be administered orally QD for a total daily dose of 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 36 mg or 48 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: MK-8189 4 mg tablet(s) will be administered orally QD for a total daily dose of 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 36 mg or 48 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: MK-8189 4 mg tablet(s) will be administered orally QD for a total daily dose of 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 36 mg or 48 mg.
Study: NCT03489018

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV10
Description: Experimental arms will receive a lower dose of the intervention than the marketed dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV10
Description: Experimental arms will receive a lower dose of the intervention than the marketed dose.
Study: NCT03565068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: MK-8189 4 mg tablet(s) will be administered orally QD for a total daily dose of 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 36 mg or 48 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: MK-8189 dose-matching placebo tablets will be administered orally QD.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: MK-8189 dose-matching placebo tablets will be administered orally QD.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: MK-8189 dose-matching placebo tablets will be administered orally QD.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: MK-8189 dose-matching placebo tablets will be administered orally QD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background AAP Therapy
Description: Participants with schizophrenia in Panel C will be on background therapy with an AAP medication (e.g., olanzapine, quetiapine, paliperidone, asenapine, iloperidone, aripirprazole, lurasidone, risperidone \[not to exceed daily dose of 6 mg\], or ziprasidone) throughout the study. Participants should be on a stable and well tolerated treatment regimen for at least 2 months prior to screening. NOTE: clozapine is not allowed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Background AAP Therapy
Description: Participants with schizophrenia in Panel C will be on background therapy with an AAP medication (e.g., olanzapine, quetiapine, paliperidone, asenapine, iloperidone, aripirprazole, lurasidone, risperidone \[not to exceed daily dose of 6 mg\], or ziprasidone) throughout the study. Participants should be on a stable and well tolerated treatment regimen for at least 2 months prior to screening. NOTE: clozapine is not allowed.
Study: NCT03118284

Intervention type: OTHER
Intervention: urine collection

Intervention type: OTHER
Intervention: Blood collection

Intervention type: OTHER
Intervention: Blood collection

Intervention type: BEHAVIORAL
Intervention: NRS
Study: NCT01949688

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLA-A*2402 or A*0201 restricted peptides
Description: Open Label, Non-Randomized, Safety/Efficacy study:~1. HLA-A\*2402-positive patients will be vaccinated subcutaneously once a week with HLA-A\*2402 restricted peptides for VEGF-R1 and VEGF-R2 with adjuvant.~2. HLA-A\*0201-positive patients will be vaccinated subcutaneously once a week with HLA-A\*0201 restricted peptides for VEGF-R1 and VEGF-R2 with adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLA-A*2402 or A*0201 restricted peptides
Description: Open Label, Non-Randomized, Safety/Efficacy study:~1. HLA-A\*2402-positive patients will be vaccinated subcutaneously once a week with HLA-A\*2402 restricted peptides for VEGF-R1 and VEGF-R2 with adjuvant.~2. HLA-A\*0201-positive patients will be vaccinated subcutaneously once a week with HLA-A\*0201 restricted peptides for VEGF-R1 and VEGF-R2 with adjuvant.
Study: NCT01454635

Intervention type: DRUG
Group type: OTHER
Intervention: Sertraline
Description: dosage,frequency and duration
Study: NCT02261584

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microwave Thermal Coagulation
Description: Microwave thermal coagulation of splenic parenchyma.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Partial Splenic Embolization
Description: Femoral artery approach will be used for splenic artery catheterization with the tip of the catheter always well advanced selectively into the splenic artery. Embolizing agent will be injected in small increments. Arteriography in between divided doses will be done to document the extent of devascularization.
Study: NCT01226914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVICEL
Description: EVICEL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: EVICEL
Description: EVICEL
Study: NCT01231139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Intravenous paracetamol, 1 gram (100mls), administered over 30 minutes (every 4 hours for 3 days).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride Schedule:
Description: Identical placebo: 100mls saline given intravenous over 30 minutes (every 4 hours for 3 days)
Study: NCT02458001

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAFFRON stepped care
Description: Behavioral: SAFFRON stepped care Stepped care (Improving Access to Psychological Therapies, 2012; Richards et al., 2012) adapted for the gynaecological cancer setting to produce a 3-step model including a clinical assessment and treatment algorithm.~Assessment Algorithm FSFI Interventions~Level 1:~Best available self-help literature on psychosexual difficulties after cancer as judged by the project team and two patient advocates.~Level 2:~A 3-5 session manualised psycho-educational intervention delivered fortnightly by study trained CNSs with taping and supervision for adherence to protocol and manual.~Level 3:~16 weekly session manualised brief psychotherapy adaptation of InterPersonal Therapy, IPT (Interpersonal Psychotherapy for Sexual Adjustment post Gynaecological Cancer, IPT-APGyC)
Study: NCT03626532

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Description: The MBSR program is a mind-body approach developed by Kabat-Zinn to reduce pain and stress through mindfulness meditation. MBSR is a form of mental training characterized by the self-regulation of attention and focal orientation to present moment experiences. Mindfulness practice is thought to effectively promote emotional and cognitive control. Mindfulness includes directing awareness away from thoughts, emotions and sensations towards some specific anchor to the present, such as the breath. Participants will engage in various practices including breath awareness, body scans, mindful listening, etc.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Education (LifeEd)
Description: This group will engage in light stretching exercises at each session. They will also be provided with information drawn from the scientific literature on topics related to healthy aging, including physical activity, sedentary behavior, nutrition, hydration, stress, sleep, and cognitively stimulating activities. Group discussion will be incorporated throughout.
Study: NCT01008475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMD 525797 250 mg
Description: EMD 525797 will be administered at a target dose of 250 mg as a 1-hour intravenous infusion for every 2 week until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMD 525797 500 mg
Description: Safety part: EMD 525797 will be administered at a target dose of 500 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .~Randomized part: EMD 525797 will be administered at a target dose of 500 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMD 525797 500 mg
Description: Safety part: EMD 525797 will be administered at a target dose of 500 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .~Randomized part: EMD 525797 will be administered at a target dose of 500 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent.